

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Ciltacabtagene autoleucl for treating relapsed or refractory multiple myeloma**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

UK Myeloma Forum noted that CAR-Ts are often commissioned in few specialist centres. This might create health inequality for people who live in different geographical areas and might not have the means to travel to specialist centres.
--

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

Where similar issues have been raised in previous appraisals (e.g. TA559 and TA567) the commissioning expert from NHS England confirmed that national multidisciplinary teams would be established to ensure equality of referral and treatment access. This is not a relevant equality issue.
--

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No
----

- |   |
|---|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes |
|---|

to the matrix been made?
No

**Approved by Associate Director (name):** Ross Dent

**Date:** 02/03/21